Journal
ALZHEIMERS RESEARCH & THERAPY
Volume 10, Issue -, Pages -Publisher
BMC
DOI: 10.1186/s13195-018-0439-y
Keywords
Alzheimer's disease; Biomarkers; Familial Alzheimer's disease; Presenilin 1; Neurofilament light
Categories
Funding
- Instituto de Salud Carlos III [PI160235]
- European Regional Development Fund: Una manera de hacer Europa
- Leonard Wolfson Experimental Neurology Centre
- Wellcome Trust Multi-User Equipment Grant
- UK Dementia Research Institute
- European Research Council
- MRC [G116/143, UKDRI-1003, UKDRI-1001, G0801306, G0601846, G0401247] Funding Source: UKRI
Ask authors/readers for more resources
BackgroundBiomarkers that can track disease onset and progression in autosomal dominant Alzheimer's disease (ADAD) are needed. We investigate whether serum neurofilament light (NfL) concentration is associated with clinical and cerebrospinal fluid (CSF) markers in ADAD. We also evaluate serum NfL differences between clinical groups.MethodsSerum NfL was measured cross-sectionally in 60 individuals from ADAD families using an ultrasensitive immunoassay on the Single molecule array (Simoa) platform and longitudinally in an exploratory study in a subset of six mutation carriers. Spearman coefficients assessed associations between serum NfL and relevant measures. Differences between groups were evaluated by Kruskal-Wallis and Mann-Whitney U tests.ResultsForty-two participants were mutation carriers: 22 symptomatic (SMC) and 20 asymptomatic (AMC). Eighteen subjects were non-carriers and cognitively normal (controls (CTR)). Serum NfL correlated with the estimated years from symptoms onset across mutation carriers (rho=0.75, p<0.001). In mutation carriers, serum NfL also showed strong correlation with clinical (rho=0.70, p<0.001) and cognitive (rho=-0.77, p<0.001) measures and CSF NfL, total tau and phosphorylated tau levels (rho=0.72, 0.71, and 0.71, respectively, all p<0.001). Serum NfL concentration was higher in SMC than in AMC and CTR.ConclusionsSerum NfL might be a feasible non-invasive biomarker to track disease onset and severity in ADAD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available